Climb Bio Q2 net loss widens on pipeline advancement
CLYM•Outlook and financing extend cash runway
Climb Bio expects to initiate CLYM116 Phase 2 dosing in IgA nephropathy in Q3 2026.
The company anticipates data from pMN, ITP, and SLE studies in Q4 2026.
Climb Bio completed a $110 million private placement, which it said extends its cash runway into the second half of 2028.
Q2 net loss widens as operating expenses rise
Climb Bio's second-quarter net loss widened year over year as operating expenses increased.
The company reported a Q2 net loss of $13.50 million and operating expenses of $15.36 million.
Pipeline advancement and trial progress drive expenses
The company said increased research and development expenses were driven by progress in clinical programs for budoprutug and CLYM116.
Climb Bio cited ongoing enrollment and new safety and efficacy data from multiple clinical trials as milestones achieved in the quarter.
